title: Is there increasing evidence that the risks of rhAPC may outweigh its benefits?
authors.forename: Maria
authors.initials: M
authors.lastname: Plataki
authors.forename: Katerina
authors.initials: K
authors.lastname: Vaporidi
authors.forename: Dimitris
authors.initials: D
authors.lastname: Georgopoulos
mesh_terms: D000890:Anti-Infective Agents; D000075202:Contraindications; D019317:Evidence-Based Medicine; D006801:Humans; D011486:Protein C; D011994:Recombinant Proteins; D018570:Risk Assessment; D018805:Sepsis / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated